8-K current report · filed Nov 19, 2026

PALVELLA THERAPEUTICS, INC. (PVLA) 8-K Current Report: November 19, 2026

Item 7.01Item 8.01Item EX-99.1Item EX-99.2PVLA overview

Short answer

PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on November 19, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). New QTORIN™ program announced as the third product candidate from Palvella’s platform.

PALVELLA THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • New QTORIN™ program announced as the third product candidate from Palvella’s platform
  • Investor conference call scheduled November 19, 2026 at 8:30 a.m. Eastern Time
  • Strategic significance: expands the development pipeline and provides investors new program details via Exhibit 99.1

Item 8.01 · Other Events

  • Third QTORIN™ product candidate announced for Extramammary Paget’s disease
  • Expands PVLA’s pipeline into a rare dermatologic cancer indication
  • Press release details and development status available in Exhibit 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Corporate presentation positions QTORIN™ docetaxel as a potential first FDA-approved EMPD therapy for an estimated >10k U.S. patients
  • Human docetaxel evidence: 51.6% ORR in 93 patients, but 24.7% discontinued for adverse events and 52.7% experienced ≥Grade 3 neutropenia
  • QTORIN™ formulation targets localized epidermal delivery, potentially reducing systemic exposure versus I.V. docetaxel
  • IND-enabling activities initiated, with FDA meeting planned for 1H 2027 and Phase 2 development expected after a pre-IND meeting
  • 505(b)(2) pathway could support development efficiency, but formulation performance and clinical tolerability remain key execution risks

Item EX-99.2 · Exhibit EX-99.2

  • New QTORIN™ docetaxel program targeting EMPD, a serious rare cancer affecting more than 10,000 U.S. patients
  • Potential first FDA-approved EMPD therapy, addressing repeated disfiguring surgeries and high recurrence rates
  • IND-enabling activities underway, with FDA meeting planned for first half of 2027
  • Phase 2 study planned after regulatory interactions, creating a new clinical development milestone
  • Program expands Palvella’s QTORIN™ pipeline to three product candidates, all investigational and unapproved

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PALVELLA THERAPEUTICS, INC. 8-K filings

Get the next PVLA 8-K as it lands

Follow PVLA for push alerts, or ask the research agent what this filing means.